137 related articles for article (PubMed ID: 26396525)
1. Association between ambient carbon monoxide and secondary hyperparathyroidism in nondiabetic patients undergoing peritoneal dialysis.
Weng CH; Hu CC; Yen TH; Huang WH
Ther Clin Risk Manag; 2015; 11():1401-8. PubMed ID: 26396525
[TBL] [Abstract][Full Text] [Related]
2. Impact of environmental particulate matter and peritoneal dialysis-related infection in patients undergoing peritoneal dialysis.
Huang WH; Yen TH; Chan MJ; Su YJ
Medicine (Baltimore); 2014 Nov; 93(25):e149. PubMed ID: 25437027
[TBL] [Abstract][Full Text] [Related]
3. Environmental NO2 level is associated with 2-year mortality in patients undergoing peritoneal dialysis.
Lin JH; Yen TH; Weng CH; Huang WH
Medicine (Baltimore); 2015 Jan; 94(1):e368. PubMed ID: 25569659
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
[TBL] [Abstract][Full Text] [Related]
5. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital.
Suwan N
J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S101-5. PubMed ID: 22043575
[TBL] [Abstract][Full Text] [Related]
6. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism.
Park CW; Oh YS; Shin YS; Kim CM; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
Am J Kidney Dis; 1999 Jan; 33(1):73-81. PubMed ID: 9915270
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.
Xu J; Yang Y; Ma L; Fu P; Peng H
Int Urol Nephrol; 2019 Nov; 51(11):2027-2036. PubMed ID: 31531805
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Prevention of renal osteodystrophy in peritoneal dialysis.
Weinreich T
Kidney Int; 1998 Dec; 54(6):2226-33. PubMed ID: 9853289
[TBL] [Abstract][Full Text] [Related]
10. Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam.
; Le TG; Ngo L; Mehta S; Do VD; Thach TQ; Vu XD; Nguyen DT; Cohen A
Res Rep Health Eff Inst; 2012 Jun; (169):5-72; discussion 73-83. PubMed ID: 22849236
[TBL] [Abstract][Full Text] [Related]
11. Risk-factors for nodular hyperplasia of parathyroid glands in sHPT patients.
Jäger MD; Serttas M; Beneke J; Müller JA; Schrem H; Kaltenborn A; Ramackers W; Ringe BP; Gwiasda J; Tränkenschuh W; Klempnauer J; Scheumann GFW
PLoS One; 2017; 12(10):e0186093. PubMed ID: 29040300
[TBL] [Abstract][Full Text] [Related]
12. Microwave ablation: an effective treatment for mild-to-moderate secondary hyperparathyroidism in patients undergoing haemodialysis.
Wang G; Liu S; Liu X; Qian L; Diao Z; Liu W
Int J Hyperthermia; 2017 Dec; 33(8):946-952. PubMed ID: 28768451
[TBL] [Abstract][Full Text] [Related]
13. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
[TBL] [Abstract][Full Text] [Related]
14. Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3.
Mizumoto D; Watanabe Y; Fukuzawa Y; Yuzawa Y; Yamazaki C
Nephrol Dial Transplant; 1994; 9(12):1751-8. PubMed ID: 7708259
[TBL] [Abstract][Full Text] [Related]
15. [Nutritional status and food intake of continuous peritoneal dialysis patients with and without secondary hyperparathyroidism].
Campos SR; Gusmão MH; Almeida AF; Pereira LJ; Sampaio LR; Medeiros JM
J Bras Nefrol; 2012 Jun; 34(2):170-7. PubMed ID: 22850919
[TBL] [Abstract][Full Text] [Related]
16. [Effect of calcitriol on secondary hyperparathyroidism].
Xu H; Zhang J; Cheng X; Zhou Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):920-4. PubMed ID: 24071691
[TBL] [Abstract][Full Text] [Related]
17. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
18. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
[TBL] [Abstract][Full Text] [Related]
19. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.
Jean G; Lafage-Proust MH; Souberbielle JC; Lechevallier S; Deleaval P; Lorriaux C; Hurot JM; Mayor B; Mehdi M; Chazot C
PLoS One; 2018; 13(6):e0199140. PubMed ID: 29912988
[TBL] [Abstract][Full Text] [Related]
20. Race and sex: predictors of the severity of hyperparathyroidism in peritoneal dialysis patients.
Fan SL; Chan A; Raftery MJ; Yaqoob MM
Nephrology (Carlton); 2006 Feb; 11(1):15-20. PubMed ID: 16509926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
